Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Sosei Group ( (JP:4565) ).
Nxera Pharma announced a significant milestone in its collaboration with AbbVie, receiving a US$10 million payment for identifying validated molecules targeting neurological diseases. This achievement underscores the productivity of their partnership, leveraging Nxera’s NxWave™ platform, and positions the company for further financial gains through potential future milestones and royalties.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen899.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma is a technology-driven biopharmaceutical company focused on developing new specialty medicines to address unmet medical needs in Japan and globally. The company operates an agile commercial business in Japan and the broader APAC region, leveraging its unique NxWave™ discovery platform to advance a pipeline of over 30 active programs targeting areas such as obesity, metabolic disorders, neurology/neuropsychiatry, and immunology and inflammation. Nxera employs approximately 400 people across key locations in Japan, the UK, Switzerland, and South Korea, and is listed on the Tokyo Stock Exchange.
YTD Price Performance: -5.92%
Average Trading Volume: 755,336
Technical Sentiment Signal: Sell
Current Market Cap: Yen89.23B
Learn more about 4565 stock on TipRanks’ Stock Analysis page.